恒瑞医药利润质量分析  

Analysis of Profit Quality of Hengrui Pharmaceuticals

作　　者：崔寒莹 杨昌红 

机构地区：[1]河北地质大学管理学院,河北 石家庄

出　　处：《世界经济探索》2024年第4期526-533,共8页World Economic Research

摘　　要：近年来,上市公司财务造假事件时有发生,导致营业收入与利润数量的虚增,简单的利润数量分析已经不能满足利益相关者的需求,因此,利润质量分析为行业和企业研究提供新思路。利润质量是对企业盈利能力的分析评判,为企业所有者和利益相关者分析企业盈利能力,可持续发展能力提供了理论支持。本文以医药制造业上市公司江苏恒瑞医药股份有限公司(以下简称“恒瑞医药”)为例,着重分析利润质量的含金量和持续性,从而分析出恒瑞医药利润质量状况,发掘出其中的问题,并提出对策建议。*第一作者。#通讯作者。In recent years, financial fraud incidents have occurred frequently among listed companies, resulting in inflated revenue and profit quantities. Simple profit quantity analysis can no longer meet the needs of stakeholders. Therefore, profit quality analysis provides new ideas for industry and enterprise research. Profit quality is the analysis and evaluation of a company’s profitability, providing theoretical support for owners and stakeholders to analyze the company’s profitability and sustainable development capabilities. This article takes Jiangsu Hengrui Pharmaceuticals Co., Ltd. (hereinafter referred to as “Hengrui Pharmaceuticals”), a listed company in the pharmaceutical manufacturing industry, as an example, focusing on analyzing the gold content and sustainability of profit quality, in order to analyze the profit quality status of Hengrui Pharmaceuticals, discover its problems, and propose countermeasures and suggestions.

关 键 词：医药制造业 恒瑞医药 盈利能力 利润质量 核心利润 

分 类 号：F42[经济管理—产业经济]